Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01967173 · ClinicalTrials.gov registry record · Phase 3
Best African American Response to Asthma Drugs
A Phase 3 study, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 574
- Enrollment target
NCT01967173 is a Phase 3 study that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 574 participants.
The verdict
NCT01967173, a Phase 3 study, has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 574 participants
- Enrollment target
Study Summary
The purpose of this study is to find the best asthma treatment to add for Blacks who have asthma that is not well controlled on a low dose of inhaled steroid. This study will also try to find out if Black adults and children differ in how they respond to the medications used in this study.
Interventions
- DRUG Flovent Diskus® 100 mcg
- DRUG Flovent Diskus® 250 mcg
- DRUG Flovent Diskus® 500 mcg
- DRUG Advair Diskus® 100/50 mcg
- DRUG Advair Diskus® 250/50 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 574 participants |
| Start Date | 2014-02 |
| Est. Completion | 2017-07-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01967173
The ClinicalTrials.gov registry entry for NCT01967173 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 574 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Flovent Diskus® 100 mcg is the first listed.
NCT01967173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01967173 about?
NCT01967173 is a clinical study titled "Best African American Response to Asthma Drugs". The purpose of this study is to find the best asthma treatment to add for Blacks who have asthma that is not well controlled on a low dose of inhaled steroid. This study will also try to find out if Black adults and children differ in how they respond to the medications used in this study.
What is the current status of trial NCT01967173?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 574 participants. The study started on 2014-02. Estimated completion is 2017-07-01.
What interventions are being tested in trial NCT01967173?
The interventions under investigation include: Flovent Diskus® 100 mcg (DRUG), Flovent Diskus® 250 mcg (DRUG), Flovent Diskus® 500 mcg (DRUG), Advair Diskus® 100/50 mcg (DRUG), Advair Diskus® 250/50 mcg (DRUG).
Who is sponsoring clinical trial NCT01967173?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.